10-Q: Arcadia Biosciences Reports Q2 2024 Results, Highlights Strategic Asset Sales

Arcadia Biosciences reports a net income of $1.1 million for Q2 2024, driven by strategic asset sales and reduced operating expenses, while also noting concerns about its ability to continue as a going concern.

Summary

• Arcadia Biosciences reported a net income of $1.1 million for the second quarter of 2024, a significant improvement compared to a net loss of $8.6 million for the same period last year.
• The company's revenue remained relatively stable at $1.3 million, with product revenue slightly increasing by 1% year-over-year.
• A major contributor to the positive results was a $4.0 million gain from the sale of its non-GMO resistant starch durum wheat trait to Corteva AgriScience.
• Arcadia also sold its GoodWheat brand to Above Food Corp. for a net consideration of $3.7 million, receiving a $6.0 million promissory note and paying $2.0 million in cash.
• Operating expenses decreased significantly due to a gain on the sale of intangible assets and reduced research and development costs.
• Despite the positive quarter, the company acknowledges substantial doubt about its ability to continue as a going concern, with cash and cash equivalents of $5.5 million, short-term investments of $2.6 million, and a current note receivable of $1.8 million as of June 30, 2024.
• The company had a net loss of $1.4 million and net cash used in operations of $5.7 million for the six months ended June 30, 2024.
• Arcadia is exploring options to raise additional funds through debt or equity financing and may consider additional partner arrangements.

Sentiment

Score: 4

Explanation: While the company reported a positive net income for the quarter, the underlying financial health and going concern issues raise significant concerns. The strategic asset sales are a positive step, but the company's long-term viability remains uncertain.

Positives

• The company achieved a net income of $1.1 million in Q2 2024, a significant improvement from the previous year.
• Strategic asset sales, including the RS durum wheat trait and the GoodWheat brand, generated substantial revenue.
• Operating expenses were significantly reduced, contributing to the positive financial results.
• The company successfully monetized its intellectual property through the sale of the RS durum wheat trait.
• The sale of the GoodWheat brand provides a promissory note and reduces the company's operational burden.

Negatives

• The company has an accumulated deficit of $273.2 million as of June 30, 2024.
• Arcadia's existing cash and cash equivalents, short-term investments, and current note receivable are not sufficient to meet its anticipated cash requirements for the next 12-18 months.
• The company had a net loss of $1.4 million and net cash used in operations of $5.7 million for the six months ended June 30, 2024.
• The company's ability to continue as a going concern is in substantial doubt.
• Product revenues decreased by 3% for the six months ended June 30, 2024 compared to the same period in 2023.

Risks

• The company's current cash reserves are insufficient to meet its operational needs for the next 12-18 months, raising concerns about its ability to continue as a going concern.
• The company may need to raise additional funds through debt or equity financing, which could dilute existing shareholders or increase debt service obligations.
• If the company is unable to secure additional funding, it may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches.
• The company's reliance on strategic asset sales for revenue may not be sustainable in the long term.
• The company faces risks related to regulatory challenges and market saturation in the hemp market, as evidenced by the wind-down of Archipelago Ventures Hawaii.

Future Outlook

The company believes that its existing cash, cash equivalents, short-term investments, and current note receivable will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months. The company may seek to raise additional funds through debt or equity financings and may consider entering into additional partner arrangements.

Management Comments

• Management believes there are significant opportunities to grow the business by scaling Zola through retail expansion and monetizing the wheat trait portfolio.
• Management intends to evaluate potential asset sales, mergers, acquisitions, and other strategic opportunities.

Industry Context

The company's strategic shift towards asset sales and focusing on core products like Zola coconut water reflects a broader trend in the industry where companies are streamlining operations and focusing on profitable segments. The sale of the GoodWheat brand and the RS durum wheat trait indicates a move towards monetizing intellectual property and reducing operational complexity. The company's exit from the body care brands highlights the challenges faced by companies in the CBD market due to regulatory uncertainty.

Comparison to Industry Standards

• Arcadia's revenue of $1.3 million for the quarter is relatively low compared to larger agricultural biotechnology companies like Corteva, which reported billions in revenue.
• The company's net income of $1.1 million is a positive sign, but it is important to note that this was largely driven by a one-time gain from the sale of the RS durum wheat trait.
• The company's cash position of $5.5 million is concerning, as it is significantly lower than the cash reserves of many of its competitors.
• The company's decision to sell off assets like GoodWheat and the RS durum wheat trait is a common strategy for smaller biotech companies that are struggling to achieve profitability, similar to other companies that have divested non-core assets to focus on their most promising products.
• The company's focus on Zola coconut water is similar to other companies that have diversified into consumer products to generate revenue, but the company's ability to compete with established brands remains to be seen.

Related Party Transactions

• Royalty fees due to the John Sperling Foundation (JSF) were $80,000 and $58,000 as of June 30, 2024 and December 31, 2023, respectively.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity financing.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers of Zola coconut water may see changes in product availability or distribution as the company focuses on scaling the brand.
• Suppliers may face extended payment terms if the company struggles to meet its financial obligations.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will evaluate potential asset sales, mergers, acquisitions, and other strategic opportunities.
• The company will continue to invest in trial-driving activities and expand distribution of its Zola coconut water brand.
• The company will continue to evaluate ways to extract value from its proprietary wheat technology.

Key Dates

Keywords

Arcadia Biosciences, GoodWheat, Corteva, Resistant Starch, Wheat Trait, Above Food Corp, Financial Results, Asset Sale, Going Concern, Promissory Note, Zola Coconut Water